The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency by Catherine J. Spellicy et al.
PSYCHIATRY
ORIGINAL RESEARCH ARTICLE
published: 14 January 2013
doi: 10.3389/fpsyt.2012.00109
The MTHFR C677T variant is associated with
responsiveness to disulfiram treatment for cocaine
dependency
Catherine J. Spellicy 1*,Thomas R. Kosten1, Sara C. Hamon2, Mark J. Harding1 and David A. Nielsen1
1 Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine and Michael E. DeBakey V. A. Medical Center, Houston, TX, USA
2 Laboratory of Statistical Genetics, The Rockefeller University, New York, NY, USA
Edited by:
F. Gerard Moeller, University of Texas
Health Science Center at Houston,
USA
Reviewed by:
Shaolin Wang, University of Virginia,
USA
Keith Heinzerling, University of
California, Los Angeles, USA
*Correspondence:
Catherine J. Spellicy ,
Michael E. DeBakey V. A. Medical
Center, 2002 Holcombe Blvd.,
Research 151, Bldg 109, Rm 129,
Houston, TX 77030, USA.
e-mail: spellicy@bcm.edu
Objective: Disulfiram is a one of the few pharmacotherapies for cocaine addiction that
shows promise. Since disulfiram and cocaine both affect levels of global methylation we
hypothesized the MTHFR gene, whose product is involved in supplying methyl groups
for DNA and protein methylation, may be associated with responsiveness to disulfiram in
cocaine-dependent individuals. Methods: Sixty-seven cocaine-dependent patients were
stabilized on methadone for 2 weeks and then randomized into disulfiram (250 mg/day,
N=32) and placebo groups (N=35) for 10 weeks. Patients were genotyped for the MTHFR
(rs1801133, also known as C677T) polymorphism and the data was evaluated for association
with cocaine-free urines in the disulfiram or placebo groups. Data from patients that com-
pleted all 10 weeks of the study (N =56) were analyzed using repeated measures analysis
of variance (ANOVA), corrected for population structure. Results: The CT or TT MTHFR
genotype group (N = 32) dropped from 73 to 52% cocaine-positive urines on disulfiram
(p=0.0001), while the placebo group showed no treatment effect. The CC MTHFR geno-
type group (N =24) showed a smaller, but still significant, reduction in cocaine-positive
urines on disulfiram compared to placebo; 81–69% (p=0.007). Conclusion: This study
indicates that a patient’s MTHFR genotype may be used to identify individuals who might
show improved response to disulfiram treatment for cocaine dependence. Clinical Trial:
Pharmacogenetics of Disulfiram for Cocaine, clinicaltrials.gov/ct2/show/NCT00149630,
NIDA-18197-2, NCT00149630.
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INTRODUCTION
Substance abuse is a critical problem in the United States. Cocaine
is one of the most common drugs of abuse and the effects of
cocaine dependency (CD) lead to social and physiological mor-
bidities. Drug abuse and drug addiction costs employers over 122
billion dollars in lost productivity and time, and another 15 billion
dollars in health insurance costs each year [Substance Abuse and
Mental Health Services Administration (SAMHSA), 2011] indicat-
ing that substance abuse and addiction have significant economic
impact. CD also may lead to risky behaviors making HIV, illicit
opioid use, and emergency care more common [Substance Abuse
and Mental Health Services Administration (SAMHSA), 2011].
Although CD is currently without an FDA-approved phar-
macotherapy, some drugs show promise in treatment of CD, an
example of which is disulfiram (Carroll, 1993; Carroll et al., 1998,
2004; George et al., 2000; Petrakis et al., 2000). Disulfiram, also
known as Antabuse, is used to treat alcoholism via its blockage
of the conversion of acetaldehyde (a metabolite of ethanol) into
acetic acid, thereby inducing aversive physiological symptoms such
as nausea and vomiting. The exact mechanism by which disulfiram
exerts its effect to reduce cocaine cravings and/or use is not exactly
known. However, studies have shown that genetic background may
be important in determining responsiveness to disulfiram as a CD
pharmacotherapy (Kosten et al., 2012).
CD is a complex disease with a strong genetic component as
indicated by a heritability of up to 72% (Tsuang et al., 1998;
Goldman et al., 2005) and increased odds ratios up to 40.8 in
monozygotic twins as compared to dizygotic twins (Kendler and
Prescott, 1998). Studies have shown that individual genetic vari-
ants are associated with risk of substance abuse, including CD [but
usually only in select populations, e.g., OPRM1 (Berrettini et al.,
1997), Homer1 (Dahl et al., 2005), OPRD1 (Kreek et al., 2005; Crist
et al., 2012)] but also that epigenetics may play a significant role
in the disease process (e.g., Nielsen et al., 2009, 2010). Changes in
epigenetics, including chromatin structure and DNA methylation,
due to drug use, and the resulting change in gene expression are
hypothesized to contribute to the neural plasticity in drug users
that has long been considered a molecular mechanism through
which drug addiction and relapse may occur (e.g., Berke et al.,
1998; Nestler, 2001; Grimm et al., 2003; Yao et al., 2004; Shaham
and Hope, 2005; Kalivas and O’Brien, 2008; Wong et al., 2011).
Cocaine itself is known to affect gene expression via regulating
heterochromatin (Maze et al., 2011) and other epigenetic factors
(Nielsen et al., 2012b).
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Disulfiram, although not a drug of abuse, also falls into this cat-
egory of pharmacotherapies that may modify the epigenetic land-
scape. Disulfiram causes hypomethylation in tumor cell lines via its
inhibition of DNA methyltransferase 1 (DNMT1; Lin et al., 2011).
DNMT1 is an enzyme involved in maintenance of DNA methyla-
tion patterns following mitosis (Kinney and Pradhan, 2011).
In this study, we chose to examine the relationship between
response to disulfiram (in terms of cocaine-positive urines over
time) and a single nucleotide polymorphism (SNP, rs1801133, also
known as C677T) in the gene coding for 5,10-methylene tetrahy-
drofolate reductase (MTHFR), whose product is central to the
folic acid metabolic cycle (see Figure 1). The folate cycle is crit-
ical to normal cellular function via supplying metabolites used
FIGURE 1 | Schematic of the folic acid metabolic cycle. Dietary folate
(vitamin B12) is converted to dihydrofolate (DHF), and subsequently
metabolized to tetrahydrofolate (THF) by dihydrofolate reductase (DHFR).
THF is converted to 5,10-methylene THF by methylenetetrahydrofolate
dehydrogenase 1 (MTHFD1), then to 5-methyl THF by methylene
tetrahydrofolate reductase (MTHFR). 5-methyl THF is demethylated and
combined with homocysteine to form methionine by
5-methyltetrahydrofolate-homocysteine methyltransferase reductase
(MTRR). Methionine is transformed to S-adenosyl methionine (SAM) by
methionine S-adenosyltransferase (MAT). SAM-dependent
methyltransferases metabolize SAM into S-adenysyl homocysteine (SAH)
methylating downstream targets. SAH is converted to homocysteine by
SAH hydrolase.
for nucleotide and amino acid synthesis, and for methylation of
downstream DNA and proteins. The minor T allele of rs1801133
codes for an amino acid change that leads to a more thermolabile
enzyme in vitro (Frosst et al., 1995), and has also been found to
associate with neural tube defects (NTDS) such as spina bifida,
a condition in which the neural tube, the precursor to the cen-
tral nervous system (CNS) during embryonic development, fails
to close completely leaving neural tissue open to the environment
(Whitehead et al., 1995; Harisha et al., 2010).
Given its involvement in both development and function of
the CNS, and its importance in biochemical pathways, such as
nucleotide synthesis and methylation, we hypothesized that vari-
ants in MTHFR may be associated with response to disulfiram
treatment in cocaine-dependent individuals.
MATERIALS AND METHODS
PARTICIPANTS
Ninety-three cocaine- and opioid co-dependent patients were
enrolled, consented, and stabilized on methadone treatment dur-
ing a 2-week screening period at Yale University (N = 40) and
Baylor College of Medicine (N = 53). The final number of patients
with at least one cocaine-positive urine sample, and that were
able to be genotyped, was 67. Opioid and/or cocaine dependence
was diagnosed via interview and the DSM-IV criteria. The MINI
(English Version 5.0.0, July 1, 2006; Sheehan et al., 1998) and the
ASI (McLellan et al., 1992) were performed on all participants to
obtain baseline psychiatric characteristics. Patients were excluded
based on current diagnosis of other drug or alcohol dependence
(excluding tobacco), current major medical illness not stabilized
on medications, a history of major psychiatric disorder (psychosis,
schizophrenia, bipolar), current suicidality, or an inability to read
and understand the consent form. Women of childbearing age
required a negative urine pregnancy test, use of adequate contra-
ception to prevent pregnancy during the study, and monthly preg-
nancy tests. All participants signed an informed consent approved
by Yale University and the Baylor College of Medicine Institutional
Review Boards that gave specific consent for genetic studies. Deter-
mination of ethnicity was based on self-report of ethnic/cultural
background of the patients.
This was a 12 week study in which individuals were assigned
randomly to placebo or disulfiram groups (250 mg daily).
Methadone dose increased 5 mg/day from an initial 25 mg to a
maintenance dose of 60 mg/day. Individual cognitive behavioral
therapy was provided weekly to all patients (Carroll, 1997).
Supervised urine samples were obtained three times weekly and
tested for the presence of a cocaine metabolite, benzoylecgonine,
using an Olympus AU 640 Emit system (Olympus America Inc.,
Melville, NY, USA). The threshold for a positive urine concentra-
tion was 300 ng/mL. Saliva samples were collected for genotyping.
GENOTYPING
DNAs were purified and genotyped as previously described
(Kosten et al., 2012). Briefly, 10 mL Scope mouthwash was used to
rinse the subject’s mouth for 60 s and centrifuged to obtain buccal
cells. The Gentra Puregene Buccal Cell Kit (Qiagen, Valencia, CA,
USA) was used to purify the DNAs following the manufacturer’s
recommendations.
Frontiers in Psychiatry | Addictive Disorders and Behavioral Dyscontrol January 2013 | Volume 3 | Article 109 | 2
Spellicy et al. MTHFR pharmacogenetics and disulfiram
The MTHFR C/T rs1801133 genetic variant was genotyped
using the TaqMan® (Applied Biosystems, Foster City, CA, USA)
primer-probe set (Assay ID C_1202883_20). PCR amplifications
were performed using Platinum® quantitative PCR SuperMix-
UDG (Invitrogen, Carlsbad, CA, USA) on a GeneAmp® PCR
system 9700 and read on an ABI Prism 7900 detection system.
SDS 2.2 software (Applied Biosystems, Foster City CA, USA) was
used to analyze the results. Sex was determined via the presence of a
sex-specific variant, rs11575897 in the SRY gene (C_32310143_10,
Applied Biosystems). Ten ancestry-informative markers were eval-
uated to determine ethnicity (Lao et al., 2006). All genotyping
experiments were performed in duplicate.
STATISTICAL ANALYSIS
Statistical analysis was performed as previously described (Kosten
et al., 2012). Demographic data was analyzed using chi-squared or
t -test. R version 2.9.1 (R Development Core Team, 2009) was used
to perform a repeated measures analysis of variance (ANOVA) on
the cocaine-positive urine data over time in the placebo/disulfiram
groups, and by MTHFR genotype. We performed statistical com-
parisons between conditions (disulfiram or placebo), MTHFR
genotypes (0=CC genotype, 1= all other genotypes), time (each
2 week period), and then examined potential interactions between
condition and time, and/or between condition and genotype. We
analyzed those individuals who had complete urine toxicology
data (N= 56), and as a secondary analysis, included those indi-
viduals with incomplete urine toxicology data (N = 67). We cal-
culated effect size as a partial eta-squared statistic using condition
or SNP variance over residual variance. The three general cutoffs
for effect size are the following: a small effect is 0.01, medium effect
is 0.06, and large effect is 0.14.
To determine population structure, our cohort was compared
against Centre d’Etude du Polymorphisme Humain – Human
Genome Diversity Project (CEPH-HGDP) samples (1,035 sub-
jects of 51 populations; Kosten et al., 2012) using the STRUCTURE
2.3.3 software (Pritchard et al., 2000; Hubisz et al., 2009).
RESULTS
BASELINE CHARACTERISTICS BY TREATMENT ANDMTHFR GENETICS
Sixty-seven patients, 32 that had been randomized to disulfiram
treatment group and 35 to placebo group, were genotyped. The
patients with complete urine toxicology data for the 12 weeks of
the trial included 32 individuals with a CT or TT genotype and
24 individuals with a CC genotype. The patients had a mean age
of 38 years and were mostly Caucasian (76%) and mostly male
(71%). Twenty-eight (50%) patients had previously been in a
methadone maintenance treatment program. On average, partici-
pants used cocaine for 12 years and for 17 days in the month prior
to entering this study (see Table 1). An additional 11 patients were
genotyped that had an incomplete urine toxicology and for whom
demographic data is not shown.
Twenty-eight patients (50%) reported any alcohol use his-
tory (>1 year), and 21 patients (37.5%) reported marijuana use
history. We found no significant baseline differences among the
four treatment by genotype groups in any clinical characteristics
except for cocaine use in years (“cocaine years”), but this became
non-significant after adjusting for multiple testing (p> 0.05).
Table 1 | Clinical and demographic characterization by treatment and
genotype.
MTHFR genotype Treatment
Disulfiram Placebo
CT/TT CC CT/TT CC
N 14 10 18 14
% Male 64 70 72 61
% Caucasian 93 70 89 43
% African American 0 20 6 43
% Hispanic 7 10 6 14
% Employed 69 80 67 50
Age years (SD) 36 (8.1) 42 (10.9) 37 (9.1) 43 (13.1)
Cocaine last 30 days (SD) 15 (9.4) 14 (10.9) 19 (9.2) 21(9.1)
Cocaine years (SD) 6 (4.8) 13 (8.3) 14 (9.3) 14(8.5)
% Alcohol use 36 40 39 36
% Marijuana use 57 50 44 50
% Past methadone 29 70 56 57
No significant baseline differences among the two treatment groups by genotype
in any clinical characteristics after adjusting for multiple testing (p>0.05).
When the complete urine toxicology sample (N= 56) was
compared to total sample (N= 67), there were no significant dif-
ferences between the two samples for any of the demographic
variables (Table 1). Additionally, when comparing demographic
data for the 11 individuals excluded from analysis to the individu-
als included in the final analyses (N= 56), there were no significant
differences for any of the demographic variables (p≥ 0.1).
COCAINE TREATMENT OUTCOMES BY GROUP
We divided the 67 patients who had been genotyped for the
MTHFR rs1801133 variant into two groups based on presence
of the T (minor) allele. For the first analysis, only those indi-
viduals with complete urine toxicology for the 12 week study were
included (N = 56). We first looked at all individuals in the placebo
group as compared to the disulfiram group, regardless of geno-
type. Results showed that individuals in the placebo group did not
have a significant reduction in cocaine-positive urines over time
(79% positive at week 1 versus 77% positive at week 12), while
individuals in the disulfiram group had a significant reduction in
cocaine-positive urines over time (76% positive urines at week
1 versus 59% positive urines at week 12, F = 22.38; df= 1, 332;
p< 0.0001, with an effect size of 0.065; see Figure 2).
COCAINE TREATMENT OUTCOMES BYMTHFR GENOTYPE
The T allele carrier group, which included individuals with CT
or TT MTHFR genotypes, showed better response to disulfiram
than did individuals not carrying the rs1801133 minor T allele
(F = 15.97; df= 1, 182; p< 0.0001, and an effect size of 0.0806).
The CC genotype group showed a more modest, but still signifi-
cant, difference between disulfiram and placebo (F = 7.27; df= 1,
134; p= 0.007, with an effect size of 0.0514). As shown in Figure 3,
cocaine-positive urines for the T allele patients during the two
baseline weeks were approximately 74% for both disulfiram and
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FIGURE 2 | Response to disulfiram therapy by treatment group
(N =56). Cocaine-positive urine toxicology screens are shown for each
2 week time period across the 12-week trial as percent positive urines. The
placebo treatment group (N =32) is represented by a solid line and the
disulfiram (250 mg/day) treatment group (N =24) is represented by a
dashed line. Standard error bars are shown for each time point. Only data
from study participants with complete urine toxicologies were included in
the analysis.
placebo treatment groups. These rates dropped to 52% during the
last 2 weeks of treatment for the disulfiram group and to 71% for
the placebo group (F = 6.982, df= 1,134, p= 0.009 with an effect
size of 0.0495). In comparison, baseline cocaine urines for the
CC genotype group were approximately 83% for disulfiram and
placebo treatment groups (see Figure 3). These rates decreased to
69% during the last 2 weeks for the disulfiram treatment group
and were unchanged for the placebo group.
When all individuals were analyzed together, which included
those with missing data points, the results were similar. With-
out regard to genotype, the placebo group had a non-significant
reduction in cocaine-positive urines from 80 to 75%, while the
disulfiram group had significant reduction in cocaine-positive
urines from 79 to 62% (F = 16.44, df= 1, 358; p< 0.0001). When
MTHFR rs1801133 genotype was considered in the analysis, the
T allele genotype group, again, responded better to disulfiram.
The T allele genotype group dropped from 79% cocaine-positive
urines at baseline to 52% positive urines at 12 weeks (F = 11.01;
df= 1, 198; p= 0.001), while the CC genotype group showed a less
dramatic reduction from 81% positive urines to 69% (F = 6.36;
df= 1, 154; p= 0.0127).
DISCUSSION
In this study, we tested the hypothesis that the C677T (rs1801133)
variant in MTHFR is associated with response to disulfiram treat-
ment in CD individuals. Our data support the hypothesis that
individuals who had at least one copy of the minor MTHFR (T)
rs1801133 allele showed better response to disulfiram than those
individuals without a T allele.
The SNP examined in this study, rs1801133 or C677T, is a
non-synonymous transition known to alter the enzyme activity of
MTHFR. The 677T allele codes for an alanine to valine amino acid
change and produces a thermolabile form of the enzyme that has
50–60% reduced enzyme activity at increased temperatures than
FIGURE 3 | Response of MTHFR C677T CC and CT/TT genotype groups
to disulfiram pharmacotherapy in individuals with complete urine
toxicology data (N =56). Cocaine-positive urine toxicologies are shown
for each 2 week time period across the 12-week trial in percent positive
urines. The solid line represents time points for the placebo treatment
group and the dashed line represents time points for the disulfiram
treatment group (250 mg/day). Top panel: patients with the MTHFR CT/TT
or TT genotype (disulfiram, N=14; placebo, N =18). Bottom panel: patients
with MTHFR CC genotype (disulfiram, N =10; placebo, N =14). Standard
error bars are shown for each time point.
the protein resulting from the allele with the more common 677C
variant (Frosst et al., 1995). As mentioned previously, MTHFR is
a key component of the folic acid metabolic cycle, and is therefore
central to maintaining the balance of folic acid (folate, pteroyl-
glutamic acid) to homocysteine in the body. Typically an inverse
relationship exists; as folate increases, homocysteine decreases.
Higher systemic levels of homocysteine (i.e., lower levels of folate)
correlate with decreased cognitive function, and are associated
with white matter lesions in the brain (de Lau et al., 2007, 2009).
Higher systemic levels of folate (i.e., lower levels of homocysteine)
have been found to be associated with increased cognitive func-
tion (Morris et al., 2001; Malouf and Grimley Evans, 2008; Moretti
et al., 2008; Sen and Kanani, 2009; Tangney et al., 2009). For exam-
ple, increased folate levels in elderly individuals were found to be
associated with slower cognitive decline, while increased homocys-
teine levels were associated with faster cognitive decline (Tangney
et al., 2009). Another study illustrated that elderly individuals who
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took folic acid supplements daily showed significant improve-
ment in global cognitive functioning (Malouf and Grimley Evans,
2008) and a similar effect was observed in school-aged girls sup-
plemented with both folate and iron (Sen and Kanani, 2009).
Likewise, folate deficiency in the CNS causes cognitive deficits such
as dyskinesia, psychomotor retardation, intellectual delay (Moretti
et al., 2008), and low folate levels were found to be associated with
reduced memory function (Morris et al., 2001).
5,10-Methylene tetrahydrofolate reductase is known to be a
critical player in the development of the CNS in humans. Low
folate levels are associated with increased incidence of NTDs (van
der Linden et al., 2006; Greene et al., 2009; Harris, 2009), a medical
condition in which the neural tube, the developmental precursor
to the CNS, does not close fully and leaves neural tissue open to
the environment. Folic acid supplementation was so successful in
reducing the occurrence and recurrence of NTDs that manda-
tory folate fortification of grain products was initiated by the FDA
in 1998 (MRC Vitamin Study Research Group, 1991; Czeizel and
Dudas, 1992; Food and Drug Administration, 1996; Berry et al.,
1999).
Individuals homozygous for the low activity T allele of MTHFR
have higher overall plasma levels of homocysteine (Jacques et al.,
1996; Rozen, 1997; Yang et al., 2008). The 677T variant has been
associated with various psychological conditions including depres-
sion and/or loneliness, and with attention deficit hyperactivity dis-
order in specific patient populations (Hickie et al.,2001; Krull et al.,
2008; Holmes et al., 2011; Kamdar et al., 2011; Lan et al., 2012).
Because MTHFR and folic acid metabolism are important for
providing metabolites for methylation, and because disulfiram and
cocaine can both affect DNA and/or histone methylation levels,
the pharmacogenetic effect in disulfiram treatment for CD may
be related to the interaction of these epigenetic effects. The T
allele of MTHFR variant rs1801133 has been found to be associ-
ated with higher homocysteine levels (Jacques et al., 1996; Rozen,
1997; Yang et al., 2008), and increased homocysteine levels (and its
metabolites) have been found to be associated with global DNA
hypomethylation (Yi et al., 2000; Caudill et al., 2001). In addition,
hypomethylation was observed in women carrying one minor T
allele in conjunction with folate deficiency, and in women carrying
two minor T alleles of MTHFR rs1801133 in the presence of vita-
min B6 deficiency (Axume et al., 2007; La Merrill et al., 2012). Simi-
larly, mice with one or both copies of MTHFR knocked out showed
hyperhomocysteinemia as well as global DNA hypomethylation
(Chen et al., 2001). Cocaine itself can affect epigenetics either at the
DNA or histone level. For example, acute cocaine administration
in mice increases local methylation of specific genes via upregu-
lating DNA methyltransferases in the brain (Anier et al., 2010). In
contrast, chronic cocaine administration or use decreased H3K9
histone methylation (Maze et al., 2010; Covington et al., 2011),
decreased global DNA methylation (in offspring of mice who
had been administered chronic cocaine; Novikova et al., 2008),
and decreased heterochromatinization (Maze et al., 2011). Disul-
firam also can affect the epigenetic landscape by decreasing global
DNA methylation (Lin et al., 2011). Methylation is an important
process by which gene expression is mediated, and may be the
basis of the genetic effect observed in disulfiram treatment for CD
and MTHFR genotype. Additional research is required to test this
hypothesis and to further elucidate the specific underpinnings of
the effect of MTHFR alleles on CD pharmacotherapies such as
disulfiram.
We have recently published two studies showing associa-
tions between response to disulfiram with the genes coding for
dopamine-β hydroxylase (DβH ; Kosten et al., 2012), the sero-
tonin transporter (5-HTTLPR), and tryptophan hydroxylase two
(TPH2; Nielsen et al., 2012b). These studies also illustrated a
pharmacogenetic effect in disulfiram therapy. Specifically, the first
study found that the group homozygous for the major C allele of
DβH showed a treatment response with disulfiram (e.g.,decreased
cocaine-positive urines over the 12-week trial), while the minor T
allele, which associates with lower DβH levels, did not. Nielsen
et al. (2012b), showed that subjects with at least one copy of the
minor allele of 5-HTTLPR or TPH2, or both, responded to disul-
firam therapy, while the genotype groups with the major alleles of
both genes did not show reduced cocaine-positive urines (Nielsen
et al., 2012a). With the addition of the new findings in this study,
that the C677T variant in the folate metabolism gene MTHFR is
a potential modifying factor in disulfiram pharmacotherapy for
cocaine dependence, we propose that the genetic profile of an
individual including findings such as these may be used to help in
tailoring a more effective pharmacotherapy for CD.
In conclusion, this study identifies the C677T variant in the
folate metabolism gene, MTHFR, as a potential modifying factor
in disulfiram pharmacotherapy for cocaine dependence. Specif-
ically, individuals carrying the minor T allele showed increased
response to disulfiram treatment. This finding may be useful in
tailoring treatment for CD to an individual based on genotype,
thereby increasing the efficacy of CD pharmacotherapy. However,
this is a clinical trial with a small cohort therefore replication
studies will be required to confirm these results.
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